Workflow
博美集团上涨4.99%,报8.2美元/股,总市值15.08亿美元

Group 1 - The core viewpoint of the article highlights the recent stock performance of BGM, which saw a 4.99% increase, reaching $8.2 per share, with a total market capitalization of $1.508 billion as of August 20 [1] - Financial data indicates that as of March 31, 2025, BGM's total revenue amounted to $14.3114 million, reflecting a year-on-year growth of 13.92%. However, the net profit attributable to the parent company was -$0.8612 million, representing a significant decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on innovative sectors such as biopharmaceuticals, bio-extraction, and healthcare [1] Group 2 - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium. Tetracycline raw materials are used not only for producing human antibiotics but also support the global aquaculture and livestock industries, ensuring the safety of poultry and seafood [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, which are major anticoagulants [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]